Browsing: Homepage Slider
0 Novel non-antibiotic for tuberculosis successfully tested
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully treat tuberculosis (TB) in animal…
0 Genomics in malaria – an interview with Dyann Wirth
Genomics is increasingly being adopted into both research and clinical settings. Here, we speak to Dyann Wirth about the use of genomics in the field of malaria, from what it can uncover about the parasite to the hurdles that need to be overcome moving towards elimination.
0 A peek behind the paper – John P. Hays on antibiotic resistance targets for point-of-care diagnostics
In this interview, take a look behind the scenes of a recent Future Microbiology paper on antibiotic resistance targets for point-of-care diagnostics with author, John P. Hays.
0 From TB to leprosy: financial model reveals where pipelines and investments might fall short
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
0 Future Microbiology: best of 2017
Here we review five of your favorite and most-read pieces from Future Microbiology from last year, give you access to the articles and provide an update from the authors on how their work is progressing.
1 Prion disease – has there been any success in treating human cases?
We take a look at the drugs that have been studied as treatments for confirmed prion diseases in humans – either in clinical trials, or on a compassionate, case-by-case basis – and look at what the future might hold for the treatment of prion diseases.
1 Update on Candida auris – an interview with Ana Litvintseva
In this interview, we speak to Ana Litvintseva, a Medical Mycologist and Team Lead at the Centers for Disease Control and Prevention (CDC; GA, USA) about Candida auris, its emergence and the challenges it presents.
0 Zika virus: from enemy to ally
Is Zika congenital syndrome, which affected thousands of babies born in Brazil during epidemics, associated with an increased host genetic susceptibility? And could Zika be a strong oncolytic agent against aggressive brain tumors? Find out in this opinion piece.
